(Q37392160)

20 August 2017

1 reference

title

Cephalosporin antimicrobial agents and related compounds (English)

1 reference

20 August 2017

C A Gustaferro

1

1 reference

20 August 2017

J M Steckelberg

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 October 1991

1 reference

20 August 2017

1 reference

20 August 2017

volume

66

1 reference

20 August 2017

issue

10

1 reference

20 August 2017

page(s)

1064-1073

1 reference

Oral cephalosporins in perspective

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Penetration of cefotaxime and desacetylcefotaxime into skin blister fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Resistance to third generation cephalosporins: the current situation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Clinical experience with cefmetazole sodium in the United States: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Safety of parenteral third-generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Impaired hemostasis caused by beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Immediate hypersensitivity reactions to beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

National Committee for Clinical Laboratory Standards agar dilution susceptibility testing of anaerobic gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

The in vitro antibacterial activity of ceftriaxone in comparison with nine other antibiotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Comparative in vitro activities of third-generation cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Antibacterial therapy: problems and promises, Part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Side effects of cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2961731-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0025-6196(12)61731-5

1 reference

20 August 2017

1 reference